GeoVax Labs (GOVX)
NASDAQ:GOVX
GOVX Stock Chart & Stats
$3.57
-$0.19(-7.85%)
At close: 4:00 PM EST
$3.57
-$0.19(-7.85%)
Day’s Range― - ―
52-Week Range$1.26 - $34.75
Previous CloseN/A
Volume281.82K
Average Volume (3M)1.03M
Market Cap
$3.14M
Enterprise Value-$3.59M
Total Cash (Recent Filing)$5.01M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta3.32
Next Earnings
Apr 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,223,577
10 Day Avg. Volume1,123,459
30 Day Avg. Volume1,033,800
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)2.54
Price to Sales (P/S)3.24
P/FCF Ratio-0.52
Enterprise Value/Market Cap-1.14
Enterprise Value/Revenue-1.07
Enterprise Value/Gross Profit-1.09
Enterprise Value/Ebitda0.14
Forecast
1Y Price Target
$350.00Price Target Upside9703.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-22.25
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical StudiesAdditional data announcements from clinical studies with 04S1 could be positive catalysts through 2025.
Comparative AnalysisDSMB Review Suggests GEO-CM04S1 May Be Superior to mRNA Vaccine.
Vaccine DevelopmentGEO-CM04S1 booster studies to continue, with early clinical studies showing the vaccine induces durable neutralizing antibody and T-cell-based immunity against current and future variants of SARS-CoV-2.
Bears Say
Contract TerminationTermination of the contract will not have a long-term material effect.
Project TerminationGeoVax Labs announced it received written notification from Advanced Technology International directing GeoVax to stop work on all efforts with respect to a Rapid Response Partnership Vehicle project.
GeoVax Labs News
GOVX FAQ
What was GeoVax Labs’s price range in the past 12 months?
GeoVax Labs lowest stock price was $1.26 and its highest was $34.75 in the past 12 months.
What is GeoVax Labs’s market cap?
GeoVax Labs’s market cap is $3.14M.
When is GeoVax Labs’s upcoming earnings report date?
GeoVax Labs’s upcoming earnings report date is Apr 30, 2026 which is in 33 days.
How were GeoVax Labs’s earnings last quarter?
Currently, no data Available
Is GeoVax Labs overvalued?
According to Wall Street analysts GeoVax Labs’s price is currently Undervalued.
Does GeoVax Labs pay dividends?
GeoVax Labs does not currently pay dividends.
What is GeoVax Labs’s EPS estimate?
GeoVax Labs’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does GeoVax Labs have?
GeoVax Labs has 2,223,577 shares outstanding.
What happened to GeoVax Labs’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of GeoVax Labs?
Currently, no hedge funds are holding shares in GOVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
GeoVax Labs
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
GOVX Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in the development and potential expedited approval of key vaccine candidates, along with increased industry interest and collaboration potential. However, financial challenges, including decreased revenue and increased net loss, present concerns. Overall, the positive development news is somewhat tempered by the financial performance.View all GOVX earnings summariesGOVX Stock 12 Month Forecast
Average Price Target
$350.00
▲(9703.92% Upside)